阿布扎比投资局旗下公司成为礼来资本医疗健康基金主投方

Group 1 - Abu Dhabi Investment Authority (ADIA) subsidiary becomes the main investor in GL Capital's single-asset continuation fund focused on SciClone Pharmaceuticals [1] - The estimated value of the continuation fund is approximately $230 million [1] - ADIA's private equity executive director highlighted SciClone as a leading company benefiting from the stable long-term development of China's healthcare sector [1] Group 2 - GL Capital previously led a $605 million privatization acquisition of SciClone in 2017 [1] - The establishment of the continuation fund allows GL Capital to maintain control over SciClone while facilitating further operational expansion [1]